SLC6A8 Gene

SLC6A8 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A8 Gene</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Finding in SLC6A8 Deficiency</td>
</tr>
<tr>
<td class="label">Plasma guanidinoacetate</td>
<td>Elevated 5-20x</td>
</tr>
<tr>
<td class="label">Urine guanidinoacetate</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Plasma creatine</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">CSF creatine</td>
<td>Decreased/absent</td>
</tr>
<tr>
<td class="label">Brain MRS</td>
<td>Absent creatine peak</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV)</td>
<td>Preclinical/early clinical</td>
</tr>
<tr>
<td class="label">Small molecule chaperones</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Substrate reduction (GAA)</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SLC6A8 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A8 Gene</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Finding in SLC6A8 Deficiency</td>
</tr>
<tr>
<td class="label">Plasma guanidinoacetate</td>
<td>Elevated 5-20x</td>
</tr>
<tr>
<td class="label">Urine guanidinoacetate</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Plasma creatine</td>
<td>Decreased</td>
</tr>
<tr>
<td class="label">CSF creatine</td>
<td>Decreased/absent</td>
</tr>
<tr>
<td class="label">Brain MRS</td>
<td>Absent creatine peak</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV)</td>
<td>Preclinical/early clinical</td>
</tr>
<tr>
<td class="label">Small molecule chaperones</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Substrate reduction (GAA)</td>
<td>Clinical trials</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

SLC6A8 encodes the Creatine Transporter (CRT or CreaT), a sodium/chloride-dependent transporter responsible for cellular uptake of creatine and its analog, guanidinoacetate. The transporter is essential for maintaining tissue creatine stores, particularly in brain, skeletal muscle, and heart, where creatine plays a critical role in energy metabolism through the phosphocreatine shuttle[@brauliyev2024][@stadhouders2020].

The SLC6A8 locus is on chromosome Xq28 and encodes an 11-transmembrane-domain protein of approximately 635 amino acids. Unlike most SLC6 family members that transport neurotransmitters, SLC6A8 transports creatine, a naturally occurring amino acid derivative involved in ATP regeneration. The transporter is expressed in most tissues, with particularly high expression in kidney, brain, muscle, and heart. SLC6A8 deficiency causes X-linked creatine deficiency syndrome, a severe neurodevelopmental disorder with intellectual disability, movement disorders, and often epilepsy.

Gene And Protein Architecture

SLC6A8 encodes a member of the SLC6 family with the characteristic 12-transmembrane-domain topology:

• N-terminal intracellular domain: Contains regulatory serine residues subject to phosphorylation
• Transmembrane core: Forms the substrate-binding site (S1) and the gate mechanism
• Large extracellular loop 1: Contains glycosylation sites important for surface expression
• C-terminal intracellular tail: Contains PDZ-binding motif for scaffolding protein interaction

Transport Mechanism

The creatine transporter operates as a sodium/chloride-coupled symporter:

The transport is electrogenic (net +1 charge per creatine) and driven by the sodium gradient. The Km for creatine uptake is approximately 10-50 μM, depending on cell type and expression system.

Physiologic Role In Energy Metabolism

The Phosphocreatine System

Creatine and phosphocreatine constitute an essential energy reserve system:

Creatine + ATP ↔ Phosphocreatine + ADP (Creatine kinase)

This reaction maintains ATP levels during high-energy demand or limited oxygen conditions:

• Brain: Supports neuronal energy demands during intense activity
• Skeletal muscle: Enables explosive contractions and recovery
• Heart: Provides energy reserve for contractile work

Brain Energy Metabolism

In the brain, the creatine transporter is critical for:

• Neuronal uptake: Neurons rely on astrocyte-derived creatine
• Glial function: Astrocytes store and release creatine on demand
• Blood-brain barrier: The transporter at the BBB regulates brain creatine levels
• Development: Adequate creatine is essential for neurodevelopment

SLC6A8 In Neurodegeneration

Creatine Deficiency Syndrome (CDS)

SLC6A8 deficiency is the most common cause of X-linked creatine deficiency syndrome, with an estimated incidence of 1 in 500,000-1 in 100,000 live births. The disorder manifests in males (hemizygous) with:

Core phenotype:

• Severe intellectual disability (IQ 40-70)
• Developmental delay, particularly speech
• Movement disorder (ataxia, dystonia, tremor)
• Seizures (in ~50% of patients)
• Behavioral problems (autism-like features, ADHD)
• Growth retardation in some cases

• Elevated guanidinoacetate (GAA) in plasma and urine
• Decreased creatine in plasma and CSF
• Absent creatine peak on brain MRS

Female Carriers

Heterozygous females are typically asymptomatic due to X-chromosome inactivation (lyonization), but:

• Some show mild cognitive impairment
• Rarely, symptomatic carriers have been reported
• Skewed X-inactivation can predict carrier status

Pathophysiology

The mechanisms of neuronal dysfunction in SLC6A8 deficiency include:

Therapeutic Implications

Creatine supplementation: Limited efficacy because brain uptake requires the transporter:

• Oral creatine can raise peripheral creatine but not brain levels in most patients
• Some patients show modest clinical improvement
• Combined with glycine restriction (to reduce GAA) has been tried

• AAV-mediated gene delivery in animal models shows promise
• Delivery across the BBB remains a challenge
• Early-phase human trials in development

Clinical Genetics

Variant Spectrum

Over 150 pathogenic SLC6A8 variants have been described:

• Missense variants: Predominantly in transmembrane domains
• Nonsense/truncating variants: Distributed throughout the gene
• Splice site variants: Cause exon skipping or intron retention
• Deletions/duplications: Detected by MLPA or array CGH

Inheritance Pattern

X-linked recessive. Males are affected; females are carriers. Approximately 30% of cases are de novo.

Genotype-Phenotype Correlation

• Null variants (nonsense, frameshift) cause more severe phenotype
• Missense variants with residual transport may have milder phenotype
• No clear correlation between variant type and specific features

Structural Biology

SLC6 Family Comparison

SLC6A8 shares structural features with other SLC6 transporters:

• 12-transmembrane helix architecture
• S1 substrate-binding site
• Na+ and Cl- binding sites
• Allosteric S2 site for competitive inhibitors

• Substrate-binding pocket geometry favoring creatine's zwitterionic form
• Conformational changes during transport cycle
• Dimerization interface important for function

Inhibitors and Substrates

• β-guanidinopropionic acid: Competitive inhibitor
• Cyclocreatine: Transportable creatine analog
• Guanidinoacetate: Endogenous substrate
• Various pharmaceutical companies have pursued inhibitors for potential applications in cancer metabolism

Biomarker Relevance

Diagnostic Biomarkers

Monitoring

• Serial guanidinoacetate measurements track treatment response
• Brain MRS can assess brain creatine levels non-invasively
• Clinical endpoints: developmental assessments, seizure frequency

Animal Models

Mouse Models

• Slc6a8 knockout mice: Show reduced brain creatine, cognitive deficits
• Conditional knockouts: Brain-specific deletion causes neurodegeneration
• Humanized mice: Express patient variants for functional studies

Zebrafish Models

• Morpholino knockdown reproduces brain creatine deficiency
• Used for drug screening and variant interpretation

Therapeutic Development

Current Management

• Creatine supplementation: Limited brain efficacy
• L-arginine/GAA reduction: Experimental approaches
• Seizure control: Standard antiepileptic drugs
• Supportive care: Physical, occupational, speech therapy

Emerging Therapies

Clinical Trials

Several trials are ongoing for creatine deficiency syndromes:

• Gene replacement trials
• Creative analog development
• Combination approaches

Research Tools

Functional Assays

• Radiolabeled creatine uptake: Gold standard for transport function
• Surface expression: Flow cytometry with epitope tags
• XF Seahorse: Cellular bioenergetics profiling

In Vitro Systems

• HEK293 expression: Variant characterization
• iPSC-derived neurons: Patient-specific models
• Organoids: 3D brain models

Summary

SLC6A8 encodes the creatine transporter, a sodium/chloride-dependent symporter essential for cellular creatine uptake in brain, muscle, and heart. Loss-of-function variants cause X-linked creatine deficiency syndrome, a severe neurodevelopmental disorder characterized by intellectual disability, movement disorders, and epilepsy.

Key aspects for neurodegeneration research include:

See Also

• [Creatine Deficiency Syndrome](/diseases/creatine-deficiency-syndrome)
• [Energy Metabolism](/mechanisms/energy-metabolism)
• [Phosphocreatine System](/mechanisms/phosphocreatine-system)
• [X-linked Intellectual Disability](/diseases/x-linked-intellectual-disability)
• [Guanidinoacetate](/biochemical-markers/guanidinoacetate)

External Links

• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/10328)
• [OMIM](https://www.omim.org/entry/300036)
• [UniProt](https://www.uniprot.org/uniprot/P48029)
• [Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147140)

Allen Brain Atlas

• [Human Brain Map - SLC6A8 Expression](https://human.brain-map.org/microarray/search/show?search_term=SLC6A8)
• [BrainSpan Transcriptome Atlas](https://brainspan.org/)

References